Skip to main content
Article thumbnail
Location of Repository

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing

By K.A. Birdwell, B. Decker, J.M. Barbarino, J.F. Peterson, C.M. Stein, W. Sadee, D. Wang, A.A. (Alexander) Vinks, Y. He, J.J. (Jesse) Swen, J.S. Leeder, R.H.N. (Ron) van Schaik, K.E. Thummel, T.E. (T.) Klein, K. Caudle and I.A.M. MacPhee


Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased doseĆ¢ djusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at

Year: 2015
DOI identifier: 10.1002/cpt.113
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.